Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests

International Journal of Cardiology

Volumn 166, Issue 1, 2013, Pages 126-131

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Sunder Plassmann, Raute ^a   Mannhalter, Christine ^a   Steiner, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clopidogrel; CYP2C9; Platelet function testing

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C9;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; CELL ASSAY; CONTROLLED STUDY; CYTOCHROME P450 2C9 GENE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HIGH ON TREATMENT RESIDUAL PLATELET REACTIVITY; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; OBSERVATIONAL STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE FUNCTION ANALYZER; VASCULAR STENT; VASODILATOR STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION ASSAY;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84877772588     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.010     Document Type: Article

References (39)

1. M. Cattaneo P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents Eur Heart J 27 2006 1010 1012
2. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
3. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
4. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
5. D.J. Angiolillo, E. Bernardo, and D. Capodanno Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J Am Coll Cardiol 55 2010 1139 1146
6. D. Erlinge, C. Varenhorst, and O.O. Braun Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo J Am Coll Cardiol 52 2008 1968 1977
7. N. Bonello-Palot, S. Armero, and F. Paganelli Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
8. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
9. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 2010 37 42
10. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
11. T. Geisler, D. Grass, and B. Bigalke The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
12. T. Gremmel, and S. Panzer Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel Thromb Haemost 106 2011 211 218
13. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
14. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
15. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
16. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2011 199 206
17. P.A. Gurbel, K.P. Bliden, and K. Guyer Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
18. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
19. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
20. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
21. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
22. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb Haemost 101 2009 333 339
23. R. Paniccia, E. Antonucci, and A.M. Gori Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients J Thromb Haemost 5 2007 1839 1847
24. M. Lordkipanidze, C. Pharand, T.A. Nguyen, E. Schampaert, D.A. Palisaitis, and J.G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur Heart J 29 2008 2877 2885
25. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent Thromb Res 128 2011 352 357
26. J. Kirchheiner, and J. Brockmoller Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 77 2005 1 16
27. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
28. B. Linnemann, J. Schwonberg, H. Mani, S. Prochnow, and E. Lindhoff-Last Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary J Thromb Haemost 6 2008 677 683
29. B. Shenkman, S. Matetzky, and P. Fefer Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests Thromb Res 122 2008 336 345
30. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
31. T. Geisler, H. Langer, and M. Wydymus Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
32. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
33. B. Giusti, A.M. Gori, and R. Marcucci Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
34. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
35. A. Harmsze, J.W. van Werkum, and H.J. Bouman Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation Pharmacogenet Genomics 20 2010 18 25
36. A.M. Harmsze, J.W. van Werkum, J.M. Ten Berg, B. Zwart, H.J. Bouman, N.J. Breet, A.W. van 't Hof, H.J. Ruven, C.M. Hackeng, O.H. Klungel, A. de Boer, and V.H. Deneer CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053
37. C. Varenhorst, S. James, and D. Erlinge Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
38. D. Sibbing, D. Gebhard, and W. Koch Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy J Thromb Haemost 8 2010 1685 1693
39. D. Sibbing, W. Koch, and D. Gebhard Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518